Hua Li

7056694, Jun 6, 2006

Aug 11, 1999

09/762594

Vassilios Papadopoulos - North Potomac MD, US
Hua Li - North Potomac MD, US

Georgetown University - Washington DC

C07H 21/04
C12N 1/20
C12N 15/09
C12N 5/00
C12P 21/00

435 691, 435 701, 4352523, 4353201, 435325, 435 711, 536 231, 536 235, 530350

The present invention relates to nucleic acids encoding peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), and nucleic acids that hybridize or are variant of nucleic acids encoding the peripheral-type benzodiazepine receptor (PBR)-associated proteins (PAPs), which are capable of encoding proteins that regulate the function of PBRs affecting both steroid biosynthesis and mediating cholesterol delivery as well as other PBR-mediated functions.

7351803, Apr 1, 2008

May 29, 2003

10/449566

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Gaithersburg MD, US
Hua Li - North Potomac MD, US
Nadine Tuaillon - Sykesville MD, US

Macrogenics, Inc. - Rockville MD

C07K 16/00
C12P 21/08
C07K 17/00

5303871, 5303873, 5303881, 53038822

CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.

7618628, Nov 17, 2009

Jun 4, 2007

11/757932

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Bethesda MD, US
Hua Li - North Potomac MD, US
Nadine Tuaillon - Sykesville MD, US

Macrogenics Inc. - Rockville MD

A61K 39/395
C07K 16/00

4241301, 5303871

CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.

7700100, Apr 20, 2010

Jan 13, 2004

10/756153

Leslie S. Johnson - Darnstown MD, US
Hua Li - Gaithersburg MD, US
Nadine Tuaillon - Gettysburg PA, US

Macrogenics, Inc. - Rockville MD

A61K 39/395

4241341, 4241441, 4241851, 4241921

The present invention relates to molecules, preferably soluble (i. e. , not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of FcγRIIB, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.

7838635, Nov 23, 2010

Jun 4, 2007

11/757939

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Bethesda MD, US
Hua Li - North Potomac MD, US
Nadine Tuaillon - Sykesville MD, US

MacroGenics, Inc. - Rockville MD

C07K 16/00
C12P 21/08
C07K 14/00
C12N 15/00

5303871, 5303873, 5303881, 53038822

CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.

20020143942, Oct 3, 2002

Sep 11, 2001

09/950501

Hua Li - Plainsboro NJ, US
Rafael Alonso - Cranbury NJ, US

G06F015/173
G06F007/00
G06F017/30

709/225000, 707/010000

A storage area network (SAN) resource manager is adapted to provide common management of storage devices in a network that comprises a heterogeneous SAN in which different storage devices are separately managed by different SAN subsystems management applications that communicate with storage device management agents residing on the storage devices to set operational parameters of and receive management information from the storage devices. The SAN resource manager communicates with the SAN subsystems management applications, causing each SAN subsystems management application to set operational parameters of and receive management information from the storage devices it manages and to communicate received management information to the SAN resource manager. The SAN resource manager may also manage SAN networking devices, so that all SAN resources are under common management. The SAN resource manager may be operated as a stand-alone application or may be integrated with higher level management applications to place SAN resources under common management with other network resources.

20060106202, May 18, 2006

Jan 13, 2006

11/331940

Vassilios Papadopoulos - North Potomac MD, US
Hua Li - North Potomac MD, US

C07K 14/705
C07K 16/28
C12Q 1/68
G01N 33/53
C07H 21/04
C12P 21/06
A61K 39/395

530350000, 435069100, 435320100, 435325000, 435007100, 530388220, 435006000, 424143100, 536023500

The present invention relates to nucleic acids encoding PBR-associated proteins (PAPs) and methods for use in producing PAPs and methods of using PAPs. In this study we have identified proteins (PAPs) that interact with PBR protein by a yeast two-hybrid system. We used PBR as bait to screen a mouse testis cDNA library. Five clones were isolated based on their ability to interact with PBR. These proteins may be involved in the regulation of the function of PBR, serving as an endogenous ligand or allosteric modulator of the receptor.

20100196372, Aug 5, 2010

Mar 11, 2010

12/721887

Leslie S. Johnson - Darnestown MD, US
Hua Li - Gaithersburg MD, US
Nadine Tuaillon - Gettysburg PA, US

MacroGenics, Inc. - Rockville MD

A61K 39/395
A61P 37/00

4241341

The present invention relates to molecules, preferably soluble (i.e., not membrane bound) polypeptides, most preferably soluble fusion polypeptides comprising the extracellular soluble regions of an FcγR, derivatives and analogs thereof, and nucleic acids encoding same. Molecules of the invention are particularly useful for the treatment, management, or prevention of, or amelioration of one or more symptoms of, an autoimmune disease, especially for ameliorating serum platelet deficiency associated with immune thrombocytopenic purpura. The invention provides methods and compositions for enhancing the therapeutic efficacy of standard, current or experimental therapies for an autoimmune disease by administering a molecule of the invention.